Used in targeted cancer therapies, this antibody inhibits the c-Met signaling pathway, which is often overactive in various tumors such as lung, liver, and gastric cancers. It blocks hepatocyte growth factor (HGF)-mediated receptor activation, suppressing tumor growth, invasion, and metastasis. Due to its high specificity, it serves as a key reagent in diagnostic assays and immunohistochemistry for detecting c-Met expression in cancer tissues. It is also employed in research and drug development to evaluate c-Met pathway inhibition and to support the design of new biologics and antibody-drug conjugates.